Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients.

Brehm TT, Franz M, Hüfner A, Hertling S, Schmiedel S, Degen O, Kreuels B, Schulze Zur Wiesch J.

Medicine (Baltimore). 2019 Aug;98(32):e16721. doi: 10.1097/MD.0000000000016721.

2.

Comparison of the integrin α4β7 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis.

Wittner M, Schlicker V, Libera J, Bockmann JH, Horvatits T, Seiz O, Kummer S, Manthey CF, Hüfner A, Kantowski M, Rösch T, Degen O, Huber S, Eberhard JM, Schulze Zur Wiesch J.

PLoS One. 2019 Jul 29;14(7):e0220008. doi: 10.1371/journal.pone.0220008. eCollection 2019.

3.

HCV-specific CD4+ T cells of patients with acute and chronic HCV infection display high expression of TIGIT and other co-inhibitory molecules.

Ackermann C, Smits M, Woost R, Eberhard JM, Peine S, Kummer S, Marget M, Kuntzen T, Kwok WW, Lohse AW, Jacobs T, Boettler T, Schulze Zur Wiesch J.

Sci Rep. 2019 Jul 23;9(1):10624. doi: 10.1038/s41598-019-47024-8.

4.

The Clinical Perspective on Hepatitis E.

Horvatits T, Schulze Zur Wiesch J, Lütgehetmann M, Lohse AW, Pischke S.

Viruses. 2019 Jul 5;11(7). pii: E617. doi: 10.3390/v11070617. Review.

5.

[Management of seasonal influenza in 2017/2018 at a German tertiary-care hospital].

Kraef C, van der Meirschen M, Wichmann D, Kutza M, Restemeyer C, Addo MM, Lohse AW, Schmiedel S, Kluge S, Schulze Zur Wiesch J.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019 Jul;62(7):870-880. doi: 10.1007/s00103-019-02976-0. German.

PMID:
31201446
6.

No link between male infertility and HEV genotype 3 infection.

Horvatits T, Varwig-Janssen D, Schulze Zur Wiesch J, Lübke R, Reucher S, Frerk S, Addo MM, Schneider SW, Lohse AW, Luetgehetmann M, Pischke S.

Gut. 2019 May 22. pii: gutjnl-2019-319027. doi: 10.1136/gutjnl-2019-319027. [Epub ahead of print] No abstract available.

PMID:
31118248
7.

Transjugular Intrahepatic Portosystemic Shunt: A Possible Risk Factor for Direct-Acting Antiviral Treatment Failure in Patients With Hepatitis C?

Piecha F, Gänßler JM, Jordan S, Ergen C, Ittrich H, Kluwe J, Pischke S, Lohse AW, Schulze Zur Wiesch J.

Hepatol Commun. 2019 Mar 18;3(5):614-619. doi: 10.1002/hep4.1337. eCollection 2019 May.

8.

Comprehensive Review of Human Plasmodium falciparum-Specific CD8+ T Cell Epitopes.

Heide J, Vaughan KC, Sette A, Jacobs T, Schulze Zur Wiesch J.

Front Immunol. 2019 Mar 21;10:397. doi: 10.3389/fimmu.2019.00397. eCollection 2019. Review.

9.

Has Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany?

Bischoff J, Boesecke C, Ingiliz P, Berger F, Simon KG, Lutz T, Schewe CK, Schulze Zur Wiesch J, Hueppe D, Christensen S, Mauss S, Baumgarten A, Rockstroh JK; GECCO study group.

J Clin Gastroenterol. 2019 Feb 15. doi: 10.1097/MCG.0000000000001189. [Epub ahead of print]

PMID:
30789853
10.

Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8+ T Cells and Evolve at the Population Level.

Karimzadeh H, Kiraithe MM, Oberhardt V, Salimi Alizei E, Bockmann J, Schulze Zur Wiesch J, Budeus B, Hoffmann D, Wedemeyer H, Cornberg M, Krawczyk A, Rashidi-Alavijeh J, Rodríguez-Frías F, Casillas R, Buti M, Smedile A, Alavian SM, Heinold A, Emmerich F, Panning M, Gostick E, Price DA, Timm J, Hofmann M, Raziorrouh B, Thimme R, Protzer U, Roggendorf M, Neumann-Haefelin C.

Gastroenterology. 2019 May;156(6):1820-1833. doi: 10.1053/j.gastro.2019.02.003. Epub 2019 Feb 12.

11.

Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

Lemoine M, Assoumou L, De Wit S, Girard PM, Valantin MA, Katlama C, Necsoi C, Campa P, Huefner AD, Schulze Zur Wiesch J, Rougier H, Bastard JP, Stocker H, Mauss S, Serfaty L, Ratziu V, Menu Y, Schlue J, Behrens G, Bedossa P, Capeau J, Ingiliz P, Costagliola D; ANRS-ECHAM Group.

J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):e86-e94. doi: 10.1097/QAI.0000000000001936.

PMID:
30570529
12.

HVEM and CD160: Regulators of Immunopathology During Malaria Blood-Stage.

Muscate F, Stetter N, Schramm C, Schulze Zur Wiesch J, Bosurgi L, Jacobs T.

Front Immunol. 2018 Nov 13;9:2611. doi: 10.3389/fimmu.2018.02611. eCollection 2018.

13.

Stable Frequencies of HLA-C*03:04/Peptide-Binding KIR2DL2/3+ Natural Killer Cells Following Vaccination.

Ziegler MC, Grañana FB, Garcia-Beltran WF, Schulze Zur Wiesch J, Hoffmann C, Rechtien A, Lunemann S, Altfeld M.

Front Immunol. 2018 Oct 17;9:2361. doi: 10.3389/fimmu.2018.02361. eCollection 2018.

14.

Detection of a Broad Range of Low-Level Major Histocompatibility Complex Class II-Restricted, Hepatitis Delta Virus (HDV)-Specific T-Cell Responses Regardless of Clinical Status.

Landahl J, Bockmann JH, Scheurich C, Ackermann C, Matzat V, Heide J, Nuurei T, D'Antonio G, von Felden J, Sette A, Peine S, Lohse AW, Luetgehetmann M, Marget M, Sidney J, Schulze Zur Wiesch J.

J Infect Dis. 2019 Jan 29;219(4):568-577. doi: 10.1093/infdis/jiy549.

PMID:
30247653
15.

Interactions Between KIR3DS1 and HLA-F Activate Natural Killer Cells to Control HCV Replication in Cell Culture.

Lunemann S, Schöbel A, Kah J, Fittje P, Hölzemer A, Langeneckert AE, Hess LU, Poch T, Martrus G, Garcia-Beltran WF, Körner C, Ziegler AE, Richert L, Oldhafer KJ, Schulze Zur Wiesch J, Schramm C, Dandri M, Herker E, Altfeld M.

Gastroenterology. 2018 Nov;155(5):1366-1371.e3. doi: 10.1053/j.gastro.2018.07.019. Epub 2018 Jul 19.

PMID:
30031767
16.

Epidemiology, clinical and laboratory features of 24 consecutive cases of leptospirosis at a German infectious disease center.

Brehm TT, Schulze Zur Wiesch J, Lütgehetmann M, Tappe D, Eisermann P, Lohse AW, Addo MM, Schmiedel S.

Infection. 2018 Dec;46(6):847-853. doi: 10.1007/s15010-018-1181-x. Epub 2018 Jul 17.

PMID:
30019313
17.

Editorial: genotype 3 HCV-who still needs ribavirin in a pan-genotypic era? Authors' reply.

von Felden J, Vermehren J, Schulze Zur Wiesch J, Sarrazin C, Christensen S.

Aliment Pharmacol Ther. 2018 Jun;47(11):1550-1551. doi: 10.1111/apt.14648. No abstract available.

PMID:
29878436
18.

Lack of evidence for human serum albumin as major source of HEV infections.

Horvatits T, Westhölter D, Peine S, Schulze Zur Wiesch J, Lohse AW, Lütgehetmann M, Pischke S.

Transfus Med. 2018 Dec;28(6):470-471. doi: 10.1111/tme.12536. Epub 2018 Apr 30. No abstract available.

PMID:
29707836
19.

Amino Acid Substitutions within HLA-B*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8+ T Cells.

Karimzadeh H, Kiraithe MM, Kosinska AD, Glaser M, Fiedler M, Oberhardt V, Salimi Alizei E, Hofmann M, Mok JY, Nguyen M, van Esch WJE, Budeus B, Grabowski J, Homs M, Olivero A, Keyvani H, Rodríguez-Frías F, Tabernero D, Buti M, Heinold A, Alavian SM, Bauer T, Schulze Zur Wiesch J, Raziorrouh B, Hoffmann D, Smedile A, Rizzetto M, Wedemeyer H, Timm J, Antes I, Neumann-Haefelin C, Protzer U, Roggendorf M.

J Virol. 2018 Jun 13;92(13). pii: e01891-17. doi: 10.1128/JVI.01891-17. Print 2018 Jul 1.

20.

HEV-positive blood donations represent a relevant infection risk for immunosuppressed recipients.

Westhölter D, Hiller J, Denzer U, Polywka S, Ayuk F, Rybczynski M, Horvatits T, Gundlach S, Blöcker J, Schulze Zur Wiesch J, Fischer N, Addo MM, Peine S, Göke B, Lohse AW, Lütgehetmann M, Pischke S.

J Hepatol. 2018 Jul;69(1):36-42. doi: 10.1016/j.jhep.2018.02.031. Epub 2018 Mar 15.

PMID:
29551705
21.

High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.

von Felden J, Vermehren J, Ingiliz P, Mauss S, Lutz T, Simon KG, Busch HW, Baumgarten A, Schewe K, Hueppe D, Boesecke C, Rockstroh JK, Daeumer M, Luebke N, Timm J, Schulze Zur Wiesch J, Sarrazin C, Christensen S.

Aliment Pharmacol Ther. 2018 May;47(9):1288-1295. doi: 10.1111/apt.14592. Epub 2018 Mar 14.

PMID:
29536554
22.

[Combination of NAFLD Fibrosis Score and liver stiffness measurement for identification of moderate fibrosis stages (II & III) in non-alcoholic fatty liver disease].

Drolz A, Wehmeyer M, Diedrich T, Piecha F, Schulze Zur Wiesch J, Kluwe J.

Z Gastroenterol. 2018 Jan;56(1):43-50. doi: 10.1055/s-0043-124956. Epub 2018 Jan 9. German.

PMID:
29316577
23.

CD32 Expression of Different Memory T Cell Subpopulations in the Blood and Lymph Nodal Tissue of HIV Patients and Healthy Controls Correlates With Immune Activation.

Wittner M, Dunay GA, Kummer S, Bockhorn M, Hüfner A, Schmiedel S, Degen O, van Lunzen J, Eberhard JM, Schulze Zur Wiesch J.

J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):345-349. doi: 10.1097/QAI.0000000000001622.

PMID:
29293157
24.

Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals.

Debes JD, van Tilborg M, Groothuismink ZMA, Hansen BE, Schulze Zur Wiesch J, von Felden J, de Knegt RJ, Boonstra A.

Gastroenterology. 2018 Feb;154(3):515-517.e3. doi: 10.1053/j.gastro.2017.10.035. Epub 2017 Nov 2.

PMID:
29102620
25.

Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection.

Boesecke C, Ingiliz P, Berger F, Lutz T, Schewe K, Schulze Zur Wiesch J, Baumgarten A, Christensen S, Rockstroh JK, Mauss S; GECCO Study Group.

Open Forum Infect Dis. 2017 Jul 27;4(3):ofx158. doi: 10.1093/ofid/ofx158. eCollection 2017 Summer.

26.

Autoantibodies against "rods and rings"-related IMPDH2 in hepatitis C genotype 1 and DAA therapy in a "real life" cohort.

Dammermann W, Polywka S, Dettmann I, Mindorf S, Komorowski L, Wehmeyer M, Schulze Zur Wiesch J, Stöcker W, Lüth S.

Med Microbiol Immunol. 2017 Oct;206(5):379-382. doi: 10.1007/s00430-017-0516-z. Epub 2017 Aug 16.

PMID:
28815296
27.

Mucosal-associated invariant T-cell frequency and function in blood and liver of HCV mono- and HCV/HIV co-infected patients with advanced fibrosis.

Beudeker BJB, van Oord GW, Arends JE, Schulze Zur Wiesch J, van der Heide MS, de Knegt RJ, Verbon A, Boonstra A, Claassen MAA.

Liver Int. 2018 Mar;38(3):458-468. doi: 10.1111/liv.13544. Epub 2017 Sep 16.

28.

Successful treatment of chronic hepatitis C with ground ledipasvir/sofosbuvir in a patient with Crohn's disease and short bowel syndrome.

von Felden J, Scheurich C, Yamamura J, Brainard DM, Mogalian E, Lohse AW, Schulze Zur Wiesch J.

J Viral Hepat. 2018 Feb;25(2):214-215. doi: 10.1111/jvh.12768. Epub 2017 Aug 30. No abstract available.

PMID:
28783205
29.

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.

Berg T, Simon KG, Mauss S, Schott E, Heyne R, Klass DM, Eisenbach C, Welzel TM, Zachoval R, Felten G, Schulze-Zur-Wiesch J, Cornberg M, Op den Brouw ML, Jump B, Reiser H, Gallo L, Warger T, Petersen J; FINITE CHB study investigators [First investigation in stopping TDF treatment after long-term virological suppression in HBeAg-negative chronic hepatitis B].

J Hepatol. 2017 Nov;67(5):918-924. doi: 10.1016/j.jhep.2017.07.012. Epub 2017 Jul 21.

PMID:
28736139
30.

Assessment of the HIV-1 reservoir in CD4+ regulatory T cells by a Droplet Digital PCR based approach.

Dunay GA, Solomatina A, Kummer S, Hüfner A, Bialek JK, Eberhard JM, Tolosa E, Hauber J, Schulze Zur Wiesch J.

Virus Res. 2017 Aug 15;240:107-111. doi: 10.1016/j.virusres.2017.07.008. Epub 2017 Jul 16.

PMID:
28720421
31.

Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).

Wehmeyer MH, Ingiliz P, Christensen S, Hueppe D, Lutz T, Simon KG, Schewe K, Boesecke C, Baumgarten A, Busch H, Rockstroh J, Schmutz G, Kimhofer T, Berger F, Mauss S, Schulze Zur Wiesch J.

J Med Virol. 2018 Feb;90(2):304-312. doi: 10.1002/jmv.24903. Epub 2017 Nov 9.

PMID:
28710853
32.

Down-regulation of CD73 on B cells of patients with viremic HIV correlates with B cell activation and disease progression.

Kim ES, Ackermann C, Tóth I, Dierks P, Eberhard JM, Wroblewski R, Scherg F, Geyer M, Schmidt RE, Beisel C, Bockhorn M, Haag F, van Lunzen J, Schulze Zur Wiesch J.

J Leukoc Biol. 2017 May;101(5):1263-1271. doi: 10.1189/jlb.5A0816-346R. Epub 2017 Feb 13.

PMID:
28193736
33.

Circulating CXCR5+CXCR3+PD-1lo Tfh-like cells in HIV-1 controllers with neutralizing antibody breadth.

Martin-Gayo E, Cronin J, Hickman T, Ouyang Z, Lindqvist M, Kolb KE, Schulze Zur Wiesch J, Cubas R, Porichis F, Shalek AK, van Lunzen J, Haddad EK, Walker BD, Kaufmann DE, Lichterfeld M, Yu XG.

JCI Insight. 2017 Jan 26;2(2):e89574. doi: 10.1172/jci.insight.89574.

34.

High clinical manifestation rate in an imported outbreak of hepatitis E genotype 1 infection in a German group of travellers returning from India.

Pischke S, Schulze-Zur-Wiesch J, Lütgehetmann M, Kreuels B, Lueth S, Kapaun P, Benten D, Schmiedel S, Sterneck M, Lohse AW, Polywka S.

Ann Hepatol. 2017 Jan-Feb;16(1):57-62. doi: 10.5604/16652681.1226815.

35.

High Clinical Manifestation Rate in an Imported Outbreak of Hepatitis E Genotype 1 Infection in a German Group of Travellers Returning from India.

Pischke S, Schulze-Zur-Wiesch J, Lütgehetmann M, Kreuels B, Lueth S, Kapaun P, Benten D, Schmiedel S, Sterneck M, Lohse AW, Polywka S.

Ann Hepatol. 2017 Jan - Feb;16(1):57-62. doi: 10.5604/16652681.1226815.

36.

Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.

Deterding K, Spinner CD, Schott E, Welzel TM, Gerken G, Klinker H, Spengler U, Wiegand J, Schulze Zur Wiesch J, Pathil A, Cornberg M, Umgelter A, Zöllner C, Zeuzem S, Papkalla A, Weber K, Hardtke S, von der Leyen H, Koch A, von Witzendorff D, Manns MP, Wedemeyer H; HepNet Acute HCV IV Study Group.

Lancet Infect Dis. 2017 Feb;17(2):215-222. doi: 10.1016/S1473-3099(16)30408-X. Epub 2016 Oct 28.

PMID:
28029529
37.

Brief Report: Increased Frequency of CD39+ CD56bright Natural Killer Cells in HIV-1 Infection Correlates With Immune Activation and Disease Progression.

Dierks P, Wroblewski R, Eberhard JM, Martrus G, Degen O, Hertling S, Schmiedel S, Lunemann S, Hüfner A, Lohse AW, Altfeld M, van Lunzen J, Schulze Zur Wiesch J.

J Acquir Immune Defic Syndr. 2017 Apr 1;74(4):467-472. doi: 10.1097/QAI.0000000000001266.

PMID:
27930600
38.

Acute Malaria Induces PD1+CTLA4+ Effector T Cells with Cell-Extrinsic Suppressor Function.

Mackroth MS, Abel A, Steeg C, Schulze Zur Wiesch J, Jacobs T.

PLoS Pathog. 2016 Nov 1;12(11):e1005909. doi: 10.1371/journal.ppat.1005909. eCollection 2016 Nov.

39.

Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01).

Ingiliz P, Christensen S, Kimhofer T, Hueppe D, Lutz T, Schewe K, Busch H, Schmutz G, Wehmeyer MH, Boesecke C, Simon KG, Berger F, Rockstroh JK, Schulze zur Wiesch J, Baumgarten A, Mauss S.

Clin Infect Dis. 2016 Nov 15;63(10):1320-1324. Epub 2016 Aug 17.

PMID:
27535952
40.

Reduced CD161+ MAIT cell frequencies in HCV and HIV/HCV co-infection: Is the liver the heart of the matter?

Eberhard JM, Kummer S, Hartjen P, Hüfner A, Diedrich T, Degen O, Lohse AW, van Lunzen J, Schulze Zur Wiesch J.

J Hepatol. 2016 Dec;65(6):1261-1263. doi: 10.1016/j.jhep.2016.07.031. Epub 2016 Aug 1. No abstract available.

PMID:
27492054
41.

Partial recovery of senescence and differentiation disturbances in CD8+ T cell effector-memory cells in HIV-1 infection after initiation of anti-retroviral treatment.

Eberhard JM, Ahmad F, Hong HS, Bhatnagar N, Keudel P, Schulze Zur Wiesch J, Schmidt RE, Meyer-Olson D.

Clin Exp Immunol. 2016 Nov;186(2):227-238. doi: 10.1111/cei.12837. Epub 2016 Aug 23.

42.

Breadth of the HCV-specific CD4+ T-cell response in spontaneous resolvers is independent of the IL-28 haplotype.

Scheurich C, Schulze Zur Wiesch J, Kim AY, Lewis-Ximenez L, Meyer T, Polywka S, Chung RT, Lauer GM.

J Viral Hepat. 2016 Oct;23(10):831-2. doi: 10.1111/jvh.12560. Epub 2016 Jun 27. No abstract available.

PMID:
27346754
43.

Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern.

Wehmeyer MH, Zyriax BC, Jagemann B, Roth E, Windler E, Schulze Zur Wiesch J, Lohse AW, Kluwe J.

Medicine (Baltimore). 2016 Jun;95(23):e3887. doi: 10.1097/MD.0000000000003887. Erratum in: Medicine (Baltimore). 2016 Jul 18;95(28):e0916.

44.

Increased CD56(bright) NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotype.

Bhardwaj S, Ahmad F, Wedemeyer H, Cornberg M, Schulze Zur Wiesch J, van Lunzen J, Sarin SK, Schmidt RE, Meyer-Olson D.

Virol J. 2016 Apr 18;13:67. doi: 10.1186/s12985-016-0507-5.

45.

Infections complicating severe alcoholic hepatitis: Enterococcus species represent the most frequently identified pathogen.

Beisel C, Blessin U, Schulze Zur Wiesch J, Wehmeyer MH, Lohse AW, Benten D, Kluwe J.

Scand J Gastroenterol. 2016 Jul;51(7):807-13. doi: 10.3109/00365521.2016.1157887. Epub 2016 Mar 22.

PMID:
27000534
46.

High proportion of HIV late presenters at an academic tertiary care center in northern Germany confirms the results of several cohorts in Germany: time to put better HIV screening efforts on the national agenda?

Schäfer G, Kreuels B, Schmiedel S, Hertling S, Hüfner A, Degen O, van Lunzen J, Schulze Zur Wiesch J.

Infection. 2016 Jun;44(3):347-52. doi: 10.1007/s15010-016-0880-4. Epub 2016 Feb 25.

PMID:
26914449
47.

Cytokine and Chemokine Signature in Elite Versus Viremic Controllers Infected with HIV.

Platten M, Jung N, Trapp S, Flossdorf P, Meyer-Olson D, Schulze Zur Wiesch J, Stephan C, Mauss S, Weiss V, von Bergwelt-Baildon M, Rockstroh J, Fätkenheuer G, Lehmann C.

AIDS Res Hum Retroviruses. 2016 Jun;32(6):579-87. doi: 10.1089/AID.2015.0226. Epub 2016 Feb 22.

PMID:
26751176
48.

Parallel assessment of Th17 cell frequencies by surface marker co-expression versus ex vivo IL-17 production in HIV-1 infection.

Dunay GA, Tóth I, Eberhard JM, Degen O, Tolosa E, van Lunzen J, Hauber J, Schulze Zur Wiesch J.

Cytometry B Clin Cytom. 2016 Nov;90(6):486-492. doi: 10.1002/cyto.b.21352. Epub 2016 Feb 18.

49.

CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X.

Karimova M, Beschorner N, Dammermann W, Chemnitz J, Indenbirken D, Bockmann JH, Grundhoff A, Lüth S, Buchholz F, Schulze zur Wiesch J, Hauber J.

Sci Rep. 2015 Sep 3;5:13734. doi: 10.1038/srep13734.

50.

Increased Frequency of CD49b/LAG-3(+) Type 1 Regulatory T Cells in HIV-Infected Individuals.

Koch K, Koch N, Sandaradura de Silva U, Jung N, Schulze zur Wiesch J, Fätkenheuer G, Hartmann P, Romerio F, Lehmann C.

AIDS Res Hum Retroviruses. 2015 Dec;31(12):1238-46. doi: 10.1089/AID.2014.0356. Epub 2015 Aug 24.

PMID:
26192268

Supplemental Content

Loading ...
Support Center